OncoCyte Stock
Focused on cancers with large patient populations and significant unmet need.
Sign up today and learn more about OncoCyte Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About OncoCyte Stock
OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.The company believes that better and earlier detection of cancer through liquid biopsies will: Improve patient outcomes Increase the life expectancy of cancer patients Significantly reduce health care costs Current diagnostic standards fall short by many measures. At present, diagnostic tests for cancer rely on scans and then tissue samples from invasive surgical procedures to determine if a tumor is benign or malignant.
Management
President & CEO
William Annett
CFO
RUSSELL SKIBSTED
Press
genomeweb - Jul, 25 2023
Oncocyte Initiates 1-for-20 Reverse Stock Splitmorningstar - Jul, 24 2023
Oncocyte Announces 1-For-20 Reverse Stock Splitthefly - Jun, 27 2023
OncoCyte begins manufacturing transplant blood testbiospace - May, 12 2023
Oncocyte Reports First Quarter 2023 Financial Resultsgenomeweb - Apr, 15 2023
Oncocyte Lays off 20 Percent of Workforce